Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01330121
Other study ID # IRB #10-165
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2010
Est. completion date April 2011

Study information

Verified date July 2023
Source Cook County Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to evaluate patient adherence with discharge diabetes medications up to 120 days following pharmacist counseling during hospital stay about diabetes self management


Description:

It is a prospective, randomized, controlled Study. Patients randomized in a 1:1 ratio to pharmacist counseling or standard of therapy prior to discharge. Standard therapy: Nurses distribute a education pamphlet on diabetes. Pharmacist Counseling includes but is not limited to: - Reviewing and explaining their medications (dosing, side effects, route) - Reviewing symptoms and complications of hyper and hypoglycemia - Defining glycemic & non-glycemic goal levels - Explaining the importance of compliance with medications & appointments - Educating on the basics of nutrition and physical activity


Recruitment information / eligibility

Status Completed
Enrollment 130
Est. completion date April 2011
Est. primary completion date April 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Males or females - 18 to 85 years of age - Historical diagnosis of type 2 diabetes mellitus greater than one year - HbA1c concentration = 8% - Discharged from general medicine unit of John H. Stroger Jr, Hospital of Cook County - Patient with provider and prescriptions filled within CCHS Exclusion Criteria: - Type 1 diabetes mellitus - Pregnancy - Major illness or debility, that prohibits the subject from participating in the study - History of any hemoglobinopathy that may affect determination of HbA1c - Non-English speaking patients

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Pharmacist Counseling
Pharmacist Counseling includes but is not limited to: Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic & non-glycemic goal levels Explaining the importance of compliance with medications & appointments Educating on the basics of nutrition and physical activity

Locations

Country Name City State
United States John H. Stroger Jr. Hospital of Cook County Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Cook County Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adherence with discharge diabetes medications up to 120 days following pharmacist counseling during hospital stay about diabetes self management The primary efficacy endpoint will be the difference in rate of adherence with medications Adherence will be assessed at 30, 60, 90, and 120 days following discharge An average of the total adherence rate 120 days following discharge will be calculated as the primary outcome measure up to 120 days
Secondary Change in A1c after 90 days A1c measure as % and lipid panel 90 days following pharmacist counseling
To demonstrate an improvement in health literacy following pharmacist counseling on diabetes
To evaluate patient compliance with follow up appointments up to 90 days following pharmacist counseling
up to 90 days
Secondary Change in BP after 90 days BP in mm/Hg up to 90 days
Secondary Change in lipids after 90 days Lipid measurements in mg/dL up to 90 days
See also
  Status Clinical Trial Phase
Completed NCT01267448 - Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Phase 4
Active, not recruiting NCT05330247 - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study N/A
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4
Terminated NCT02373865 - Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes Phase 4
Completed NCT01741181 - Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2 Phase 4
Completed NCT01305434 - Mulberry Leaf Extract and Blood Glucose Control in Diabetics Phase 1/Phase 2
Recruiting NCT00992797 - Diabetes Intervention Trial With Vitamin D in Subjects of Nordic and Sub-Indian Ethnicity Phase 2
Completed NCT01580904 - Impact of Pharmaceutical Care in Diabetics Patients N/A
Active, not recruiting NCT00728403 - Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes Phase 2
Completed NCT00763815 - GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone Phase 3
Active, not recruiting NCT00529815 - Continuous Glucose Monitoring in Patients With Type 2 Diabetes Phase 4
Completed NCT00517465 - A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus. Phase 1
Active, not recruiting NCT00417716 - Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema Phase 3
Completed NCT00119041 - Diabetes Telemedicine Consultation: A Systems Improvement Intervention N/A
Completed NCT00600236 - HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population Phase 3
Active, not recruiting NCT05887635 - Study of Duodenal Mucosal RF Vapor Ablation in Subjects With Type-2 Diabetes Mellitus N/A
Completed NCT03903965 - Comparison of Retinal Perfusion Between Diabetic and Non-diabetic Patients With OCT Angiography After Cataract Surgery.
Completed NCT02666924 - Cooking Classes for Chinese Canadian Patients Living With Diabetes N/A
Recruiting NCT02501850 - The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Phase 4
Completed NCT01765517 - Study to Explore the Effects of Probiotics on Endotoxin Levels in Type 2 Diabetes Mellitus Patients N/A